PGNY is the ticker symbol for Progyny, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks PGNY with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is PGNY a good stock to buy?

13F Pro's AI ranking engine scores PGNY at 62.6/100, ranked #691 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for PGNY is available at https://13fpro.ai/company/PGNY. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source PGNY data?

All Progyny, Inc. fundamentals and ownership data come directly from SEC EDGAR. Progyny, Inc. files with the SEC under CIK 1551306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Progyny, Inc. PGNY

NasdaqMid CapHealthcare

13F Pro quality score

Rank #691 of 2,925TOP 25%

Why it scores 63 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$350.51M

Quarter to Jun 30

Net income

$28.05M

Quarter to Jun 30

Free cash flow

$44.21M

Quarter to Jun 30

Operating margin

11.4%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$2.26B total

BlackRock, Inc.

$334.43M-3.3%

FMR LLC

$201.93M+7.7%

VANGUARD PORTFOLIO MANAGEMENT LLC

$144.71MNew

VANGUARD CAPITAL MANAGEMENT LLC

$92.57MNew

STATE STREET CORP

$87.15M-1.9%

AMERIPRISE FINANCIAL INC

$79.67M-2.2%

FORT WASHINGTON INVESTMENT ADVISORS INC /OH/

$73.46M-5.4%

GEODE CAPITAL MANAGEMENT, LLC

$56.78M-3.6%

CITADEL ADVISORS LLC

$51.48MNew

DIMENSIONAL FUND ADVISORS LP

$48.68M+7.3%

Soleus Capital Management, L.P.

$46.19M-22.5%

MORGAN STANLEY

$44.28M-32.9%

WELLINGTON MANAGEMENT GROUP LLP

$43.15M-34.6%

DISCIPLINED GROWTH INVESTORS INC /MN

$34.07M+105.7%

LOOMIS SAYLES & CO L P

$31.16M+9.4%

BAILLIE GIFFORD & CO

$31.10M-11.6%

JANE STREET GROUP, LLC

$30.66M+614.1%

EASTERLY INVESTMENT PARTNERS LLC

$27.62M+15.0%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$27.51M+19.5%

LSV ASSET MANAGEMENT

$25.82M+5107.2%

NORTHERN TRUST CORP

$23.15M-1.9%

AQR CAPITAL MANAGEMENT LLC

$22.99M+21.5%

AMERICAN CENTURY COMPANIES INC

$22.45M+244.9%

Fideuram Asset Management (Ireland) dac

$18.39M+1018.5%

River Road Asset Management, LLC

$18.31M-6.1%

See all 313 institutional holders →

What's Driving PGNY's Business? Latest 10-Q Breakdown

23/23 datapoints verified

AI-extracted from the 10-Q filed 2026-08-07 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Progyny grew Q2 revenue 5% YoY to $350.5M while gross margin expanded 180bps to 25.5% and net income rose 64% to $28.1M, aided by lower stock-based compensation.

Biggest Revenue Drivers

Fertility benefits services$230.2M+8% YoY

Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025

Pharmacy benefits services (Progyny Rx)$120.3M+1% YoY

Increase in clients and covered lives, partially offset by the same large client non-renewal impact

Biggest Revenue Drivers

Total revenue: $350.5M+5% YoY

Fertility benefits services$230.2M+8% YoY

Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025

Pharmacy benefits services (Progyny Rx)$120.3M+1% YoY

Increase in clients and covered lives, partially offset by the same large client non-renewal impact

Largest Expense Items

Cost of services$261.2M+3% YoY

Higher medical treatment and pharmacy prescription costs, partially offset by a $3.4M decrease in stock-based compensation and the large client non-renewal impact

General and administrative$31.2M-14% YoY

$5.9M decrease in stock-based compensation as the November 2021 retention grant fully vested in late 2025, partially offset by incremental headcount costs

Sales and marketing$18.1M-2% YoY

$2.6M decrease in stock-based compensation, partially offset by higher other sales and marketing expenses and incremental headcount

Margins: Gross margin rose 180 basis points to 25.5% from 23.7%, driven by ongoing efficiencies in delivery of care management services and lower stock-based compensation expense.

Watch Items from the Filing

No single client accounted for more than 10% of total revenue for the six months ended June 30, 2026, though the filing notes a significant portion of revenue and clients are concentrated in the technology industry.
Revenue growth was tempered by the prior-year loss of a large client whose extended transition-of-care agreement ended June 30, 2025, creating a tougher comp base going forward.
The Consolidated Appropriations Act of 2026 (signed Feb 3, 2026) imposes new PBM disclosure, 100% rebate pass-through, and audit requirements that could affect Progyny Rx's profitability.
Board authorized a new $200M share repurchase program in May 2026 (after completing the $200M November 2025 program); $148.1M of stock was repurchased in the first half of 2026, with $168.5M still available.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PGNY

Earnings Per Share

13fpro.ai/company/PGNY

Loading ratio trend…

Progyny, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$1.3B	$58.5M	6.6%
FY 2024	10-K	$1.2B	$54.3M	5.8%
FY 2023	10-K	$1.1B	$62.0M	5.7%
FY 2022	10-K	$786.9M	$30.4M	3.0%
FY 2021	10-K	$500.6M	$65.8M	6.5%
FY 2020	10-K	$344.9M	$46.5M	2.4%

About Progyny, Inc. (PGNY): stock profile, AI score and financials

Progyny, Inc. (PGNY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGNY at 62.6/100 on a composite quality score built from its SEC filings, placing it at rank #691 of 2,925 stocks — the top 25% of the AI-ranked universe. PGNY scores in the top quartile across institutional flow (93.2), earnings quality (87.3), balance sheet strength (86.6). Shareholder dilution risk is elevated at 15.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Progyny, Inc. reports quarterly revenue of $350.5M, net income of $28.1M, an operating margin of 11.4%. Top institutional holders of PGNY by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PGNY trades on the Nasdaq exchange and files with the SEC under CIK 1551306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Progyny, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1551306 →

Progyny, Inc. PGNY

Top Institutional Holders

What's Driving PGNY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

PGNY key financials by period

PGNY insiders

Congress trading in PGNY

About Progyny, Inc. (PGNY): stock profile, AI score and financials

Progyny, Inc. PGNY

Top Institutional Holders

What's Driving PGNY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

PGNY key financials by period

Companies similar to PGNY

PGNY insiders

Congress trading in PGNY

About Progyny, Inc. (PGNY): stock profile, AI score and financials